US Stock Insider Trading | ProMIS Neurosciences Discloses 6 Insider Transactions on February 5

K-LinePoet · 2026-02-28T07:51:33+00:00

ProMIS Neurosciences disclosed stock purchase transactions by several executives and major shareholders on February 3, 2026, with ABG Management Ltd. purchasing 700,700 shares for a total of $8.5 million. The company focuses on developing antibody therapies for neurodegenerative diseases using patented technology.

K-LinePoet

2026-02-28 07:51:33

Abstract generation in progress

On February 5, 2026, ProMIS Neurosciences (PMN) disclosed six insider trading transactions. Shareholder ABG Management Ltd., holding more than 10%, purchased 700,700 shares on February 3, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 5, 2026	Executive	Johanne Kaplan	February 3, 2026	Buy	2,060	12.13	$25,000
February 5, 2026	Shareholder	Max A. Milbury	February 3, 2026	Buy	6,595	12.13	$80,000
February 5, 2026	Director	Patrick D. Kirwin	February 3, 2026	Buy	3,050	12.13	$37,000
February 5, 2026	Director	Neil Cashman	February 3, 2026	Buy	4,122	12.13	$50,000
February 5, 2026	Director	Neil K. Warma	February 3, 2026	Buy	6,183	12.13	$75,000
February 5, 2026	Shareholder with >10%	ABG Management Ltd.	February 3, 2026	Buy	700,700	12.13	$8,500,000
October 6, 2025	Shareholder	Max A. Milbury	October 3, 2025	Buy	30,400	0.49	$1,490
February 12, 2025	Director	Neil Cashman	February 10, 2025	Buy	15,000	0.97	$1,460
September 24, 2024	Director	Madge K. Shafmaster	September 20, 2024	Buy	60,000	1.25	$75,100
September 24, 2024	Director	Madge K. Shafmaster	September 24, 2024	Buy	70,000	1.30	$91,000

[Company Information]

ProMIS Neurosciences Inc. was incorporated under the Canada Business Corporations Act on January 23, 2004, and is located at 1920 Yonge Street, Toronto, Ontario. The company is leveraging its patented technology platform to develop antibody therapies, therapeutic vaccines, and other antibody-based treatment combinations for neurodegenerative diseases and other misfolded protein disorders, including Alzheimer’s disease, multiple system atrophy, and amyotrophic lateral sclerosis. The company also plans to research other synucleinopathies, such as Parkinson’s disease and Lewy body dementia, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. These diseases share a common biological cause—misfolded proteins that, if functioning normally, would perform their roles but instead become toxic and kill neurons, leading to disease. ProMIS’s technology platform exemplifies advances in drug discovery through computational power, computer-aided discovery, and artificial intelligence.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.